Cognitive and behavioral risk factors for low quality of life in survivors of childhood acute lymphoblastic leukemia.


Journal

Pediatric research
ISSN: 1530-0447
Titre abrégé: Pediatr Res
Pays: United States
ID NLM: 0100714

Informations de publication

Date de publication:
08 2021
Historique:
received: 12 05 2020
accepted: 03 10 2020
revised: 25 09 2020
pubmed: 19 11 2020
medline: 8 2 2022
entrez: 18 11 2020
Statut: ppublish

Résumé

With high survival rates for pediatric acute lymphoblastic leukemia (ALL), long-term quality of life is a prominent consideration in treatment. We concurrently evaluated cognition, behavior, and quality of life in child and adolescent ALL survivors and determined associations between them. The sample included 83 controls (mean age: 12.5 years) and 71 ALL survivors (mean age: 11.9 years, mean age at diagnosis: 3.8 years). Participants completed measures of general intellectual abilities, math achievement, and fine motor skills. Parents and teachers completed a survey assessing child participants' cognitive, behavioral, and emotional function. Parents additionally completed a survey about their child's quality of life. Survivors had lower scores on measures of working memory, processing speed, timed math, and fine motor skills (effect size 0.5-1, p < 0.001). Parents identified more problems with executive function and learning in survivors than controls (effect size > 0.7, p < 0.001), and indicated a lower quality of life in all categories evaluated (effect size > 0.7, p < 10 ALL survivors experience diffuse cognitive, behavioral, and motor impairments, which are associated with reduced quality of life. These findings underscore the need to address these challenges in ALL survivors. Compared with cancer-free peers, parents of childhood acute lymphoblastic leukemia survivors treated with chemotherapy only reported reduced quality of life. Math difficulties and behavioral problems increased the risk for reduced quality of life. Reduced quality of life is associated with mild cognitive and behavioral difficulties, suggesting that even relatively mild impairments have broad implications for ALL survivors. Screening and early intervention targeting cognitive and behavioral function may enhance quality of life for ALL survivors.

Sections du résumé

BACKGROUND
With high survival rates for pediatric acute lymphoblastic leukemia (ALL), long-term quality of life is a prominent consideration in treatment. We concurrently evaluated cognition, behavior, and quality of life in child and adolescent ALL survivors and determined associations between them.
METHODS
The sample included 83 controls (mean age: 12.5 years) and 71 ALL survivors (mean age: 11.9 years, mean age at diagnosis: 3.8 years). Participants completed measures of general intellectual abilities, math achievement, and fine motor skills. Parents and teachers completed a survey assessing child participants' cognitive, behavioral, and emotional function. Parents additionally completed a survey about their child's quality of life.
RESULTS
Survivors had lower scores on measures of working memory, processing speed, timed math, and fine motor skills (effect size 0.5-1, p < 0.001). Parents identified more problems with executive function and learning in survivors than controls (effect size > 0.7, p < 0.001), and indicated a lower quality of life in all categories evaluated (effect size > 0.7, p < 10
CONCLUSIONS
ALL survivors experience diffuse cognitive, behavioral, and motor impairments, which are associated with reduced quality of life. These findings underscore the need to address these challenges in ALL survivors.
IMPACT
Compared with cancer-free peers, parents of childhood acute lymphoblastic leukemia survivors treated with chemotherapy only reported reduced quality of life. Math difficulties and behavioral problems increased the risk for reduced quality of life. Reduced quality of life is associated with mild cognitive and behavioral difficulties, suggesting that even relatively mild impairments have broad implications for ALL survivors. Screening and early intervention targeting cognitive and behavioral function may enhance quality of life for ALL survivors.

Identifiants

pubmed: 33203967
doi: 10.1038/s41390-020-01230-7
pii: 10.1038/s41390-020-01230-7
pmc: PMC9014848
mid: NIHMS1793641
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

419-426

Subventions

Organisme : NICHD NIH HHS
ID : P50 HD103556
Pays : United States
Organisme : CIHR
ID : 703558
Pays : Canada

Informations de copyright

© 2020. International Pediatric Research Foundation, Inc.

Références

Med Care. 2001 Aug;39(8):800-12
pubmed: 11468499
Pediatr Blood Cancer. 2011 Dec 15;57(7):1197-203
pubmed: 21294244
Pediatr Blood Cancer. 2017 Sep;64(9):
pubmed: 28266135
Neuropsychol Rev. 2020 Sep;30(3):386-406
pubmed: 32720195
Cancer. 2018 Apr 1;124(7):1492-1500
pubmed: 29430634
J Clin Oncol. 2010 Oct 10;28(29):4465-72
pubmed: 20837955
J Clin Oncol. 2016 Apr 10;34(11):1239-47
pubmed: 26858334
Blood. 2015 Jul 16;126(3):346-53
pubmed: 26048910
Psychol Assess. 2015 Mar;27(1):239-48
pubmed: 25222436
Child Neuropsychol. 2018 Nov;24(8):999-1014
pubmed: 29017430
Eur J Cancer. 2013 Sep;49(14):3029-40
pubmed: 23831334
Cancer. 2018 Jan 15;124(2):417-425
pubmed: 28915338
Psychooncology. 2014 Jun;23(6):692-9
pubmed: 24497266
Cancer. 2018 Feb 1;124(3):571-579
pubmed: 29112230
Neurooncol Pract. 2015 Jun;2(2):78-87
pubmed: 27054041
Qual Life Res. 2018 Jun;27(6):1431-1443
pubmed: 29372438
Qual Life Res. 2009 Feb;18(1):5-13
pubmed: 18989755
J Cancer Surviv. 2018 Jun;12(3):398-406
pubmed: 29484542
J Paediatr Child Health. 2016 Dec;52(12):1062-1069
pubmed: 27988995
J Clin Oncol. 2015 Nov 20;33(33):3894-902
pubmed: 26460306
Blood. 2006 Aug 15;108(4):1165-73
pubmed: 16609069
Cancer Epidemiol Biomarkers Prev. 2011 Sep;20(9):1838-49
pubmed: 21844244
J Pediatr Psychol. 2017 Mar 01;42(2):220-231
pubmed: 27342301
Health Qual Life Outcomes. 2007 Jan 03;5:2
pubmed: 17201923
Neurosci Biobehav Rev. 2015 Jun;53:108-20
pubmed: 25857254
Lancet Psychiatry. 2016 Oct;3(10):965-972
pubmed: 27639661
J Pediatr Psychol. 2011 May;36(4):438-50
pubmed: 21097489
Psychol Assess. 2016 Sep;28(9):1110-8
pubmed: 27537005
Neuroimage Clin. 2020;28:102428
pubmed: 32980598
Ambul Pediatr. 2003 Nov-Dec;3(6):329-41
pubmed: 14616041
J Pediatr Psychol. 2012 May;37(4):458-66
pubmed: 22271791
Acta Paediatr. 2009 Jan;98(1):180-6
pubmed: 18826490
Leukemia. 2010 Feb;24(2):285-97
pubmed: 20016531

Auteurs

Ellen van der Plas (E)

Department of Psychiatry, University of Iowa Hospital & Clinics, Iowa City, IA, USA.

T Leigh Spencer Noakes (TL)

Mouse Imaging Centre, Hospital for Sick Children, Toronto, ON, Canada.
Translational Medicine, Hospital for Sick Children, Toronto, ON, Canada.

Darci T Butcher (DT)

Genetics & Genome Biology, Hospital for Sick Children Research Institute, Toronto, ON, Canada.
Department of Pathology and Molecular Medicine, McMaster University, Hamilton, ON, Canada.

Rosanna Weksberg (R)

Genetics & Genome Biology, Hospital for Sick Children Research Institute, Toronto, ON, Canada.
Clinical and Metabolic Genetics, Hospital for Sick Children Research Institute, Toronto, ON, Canada.
Department of Molecular Genetics, University of Toronto, Toronto, ON, Canada.
Institute of Medical Sciences, University of Toronto, Toronto, ON, Canada.

Laura Galin-Corini (L)

Translational Medicine, Hospital for Sick Children, Toronto, ON, Canada.

Elizabeth A Wanstall (EA)

Department of Psychology, The Hospital for Sick Children, Toronto, Ontario, Canada.
Department of Psychology, York University, Toronto, ON, Canada.

Patrick Te (P)

Translational Medicine, Hospital for Sick Children, Toronto, ON, Canada.
Clinical Pharmacology and Toxicology, Hospital for Sick Children, Toronto, ON, Canada.

Laura Hopf (L)

Department of Psychology, The Hospital for Sick Children, Toronto, Ontario, Canada.

Sharon Guger (S)

Department of Psychology, The Hospital for Sick Children, Toronto, Ontario, Canada.

Johann Hitzler (J)

Department of Pediatrics, Faculty of Medicine, University of Toronto, Toronto, ON, Canada.
Developmental and Stem Cell Biology, Hospital for Sick Children, Toronto, ON, Canada.
Division of Hematology/Oncology, Hospital for Sick Children, Toronto, ON, Canada.

Russell J Schachar (RJ)

Department of Psychiatry, Hospital for Sick Children, Toronto, ON, Canada.
Psychiatry Research, Hospital for Sick Children, Toronto, ON, Canada.

Shinya Ito (S)

Translational Medicine, Hospital for Sick Children, Toronto, ON, Canada.
Clinical Pharmacology and Toxicology, Hospital for Sick Children, Toronto, ON, Canada.
Pharmacology and Toxicology, Faculty of Medicine, University of Toronto, Toronto, ON, Canada.

Brian J Nieman (BJ)

Mouse Imaging Centre, Hospital for Sick Children, Toronto, ON, Canada. brian.nieman@sickkids.ca.
Translational Medicine, Hospital for Sick Children, Toronto, ON, Canada. brian.nieman@sickkids.ca.
Ontario Institute for Cancer Research, Toronto, ON, Canada. brian.nieman@sickkids.ca.
Department of Medical Biophysics, University of Toronto, Toronto, ON, Canada. brian.nieman@sickkids.ca.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH